Boston Scientific has announced that Standard and Poor’s Ratings Services has raised the company’s rating outlook to positive from negative, while affirming the company’s corporate credit rating at BB+. The Standard and Poor’s upgrade followed the Moody’s actions of 12 March when it raised the company’s outlook to stable from negative.
Standard and Poor’s said the revised rating outlook reflects: the company’s ongoing debt pay down over the past several years; maintenance of its leading market share in the drug-eluting stent market in the face of increasing competition; and prospects for (at a minimum) modest growth in cardiac rhythm management devices given recent, new product launches.
